HER2, HER3, and MRD: Drs. Previs and Green break down ASCO highlights and what they mean for the future of cancer diagnostics.
Precision oncology is evolving fast, and staying ahead means rethinking how we test, monitor, and treat cancer.
In this episode of Labcorp Perspectives: Oncology, host Dr. Rebecca Previs sits down with Dr. Michelle Green, senior manager of oncology genomics, to talk about the major highlights from the ASCO Annual Meeting.
They explore Labcorp’s HER2 expression study in breast cancer, which found significant changes in HER2 status over time, and what that means for retesting and clinical decisions. Michelle and Rebecca also discuss new data on HER3-targeting antibody-drug conjugates, including the potential for treating both breast and lung cancers, and advances in ctDNA testing across tumor types.
From molecular profiling to liquid biopsy, this episode provides a wide-ranging look at how new tools and emerging biomarkers are shaping the future of personalized oncology care.
Listen to the full conversation now.
Follow Us
Presented by Labcorp Oncology